Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003782 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
A Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,351
- Enrollment target
- 20
- Study locations
NCT00003782 is a Phase 3 study of Breast Cancer that has completed, run by NSABP Foundation. The registered enrollment target is 5,351 participants, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00003782, a Phase 3 study of Breast Cancer, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,351 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor cells remaining following surgery. It is not yet known which regimen of combination chemotherapy is more effective in treating breast cancer with positive axillary lymph nodes. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy in treating women who have undergone surgery for stage I, stage II, or stage IIIA breast cancer with positive axillary lymph nodes.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG docetaxel
- DRUG doxorubicin
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- California Cancer Center - Fresno
- Sutter Health Western Division Cancer Research Group - Greenbrae
- Scripps Cancer Center at Scripps Clinic - La Jolla
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
- Pacific Shores Medical Group - Long Beach
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center - Orange
- Comprehensive Cancer Centers of the Desert - Palm Springs
- Stanford Cancer Center at Stanford University Medical Center - Palo Alto
- Sutter Cancer Center - Sacramento
- Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego - San Diego
- Catholic Healthcare West - Westbay Region - San Francisco
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- Kaiser Permanente Medical Center - Vallejo - Vallejo
Alabama
- Comprehensive Cancer Institute - Huntsville
Alaska
- Providence Alaska Medical Center - Anchorage
Arizona
- CCOP - Western Regional, Arizona - Phoenix
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,351 participants |
| Start Date | 1999-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003782
The ClinicalTrials.gov registry entry for NCT00003782 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,351 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% higher). The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which cyclophosphamide is the first listed.
NCT00003782 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT00003782 about?
NCT00003782 is a clinical study titled "Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor cells remaining following surgery. It is not yet known which regimen of combination chemotherapy is more effective ...
What is the current status of trial NCT00003782?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,351 participants. The study started on 1999-03. Estimated completion is 2012-12.
What conditions does trial NCT00003782 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00003782?
The interventions under investigation include: cyclophosphamide (DRUG), docetaxel (DRUG), doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00003782?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003782 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.